pH响应型纳米药物用于化疗-光热协同治疗肿瘤  

Study on pH Responsive Nanomedicine in Chemo-photothermal SynergisticTherapy of Tumor

作　　者：唐昭敏 田维君 TANG Zhaomin;TIAN Weijun(School of New Energy and Materials,Southwest Petroluem University,Chengdu 610500,China)

机构地区：[1]西南石油大学新能源与材料学院,成都610500

出　　处：《材料导报》2022年第3期90-95,共6页Materials Reports

基　　金：国家自然科学基金(51803174)。

摘　　要：化疗协同光热治疗(PTT)是提高肿瘤疗效的一种新型治疗方式。本研究拟合成一种亚细胞器靶向的近红外响应纳米药物Fe_(3)O_(4)@PDA-TPP/S_(2)-PEG-hyd-DOX(Fe_(3)O_(4)-ATSPD)作为新的光热制剂,它可通过磁靶向增强肿瘤细胞的摄取,具有良好的光热稳定性和光热转化效率。在近红外光(NIR)照射下,光热剂多巴胺(PDA)产生光热效应,促使线粒体膜电位显著下降。同时,在内涵体/溶酶体低pH值环境下,Fe_(3)O_(4)-ATSPD释放偶联药物DOX进入细胞核损伤DNA,最终促使肿瘤细胞凋亡。本研究制备的纳米药物能有效整合诊断和治疗,为肿瘤治疗提供新的协同治疗策略。Chemotherapy(CT)combined with photothermal therapy(PTT)is an effective combination for the treatment of tumor.Herein,we deve-loped a subcellular-targeted NIR-responsive nanomedicine Fe_(3)O_(4)@PDA-TPP/S_(2)-PEG-hyd-DOX(abbreviated as Fe_(3)O_(4)-ATSPD)as a new photothermal agent,the intracellular uptake of which can be enhanced by magnetic targeting.Under the near-infrared(NIR)irradiation,the photothermal effect can be realized from the polydopamine photosensitizer,leading to a dramatic decrease in mitochondrial membrane potential.Simultaneously,the conjugated drugs released by low pH in endo/lysosome cause nucleus DNA damage and lead to apoptosis.This subcellular-targeted NIR-responsive nanomedicine with efficient integration of diagnosis and therapy,could significantly enhance cancer treatment by combination of chemotherapy and PTT.

关 键 词：化疗 光热治疗 协同作用 近红外 

分 类 号：R730.53[医药卫生—肿瘤]